Prevention & lipidsCross-sectional study
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
- cross-sectional study
- National Health and Nutrition Examination Survey 2011 to 2020
Authors' conclusion
Approximately 20 million U.S. adults with inadequately controlled LDL-C may be eligible for inclisiran, with the potential to prevent over 1.6 million ASCVD events over 10 years.
Study context
- Population
- U.S. adults ≥18 years with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (≥55 mg/dL if very high-risk for atherosclerotic cardiovascular disease (ASCVD) events) despite statin therapy
- Exposure
- ASCVD events in 10 years "with inclisiran" vs "without inclisiran"
- high-risk primary preventionn = 5.4 million
- diabetesn = 6.5 million
- secondary preventionn = 8.0 million
Main finding
As reported in the abstract
Estimated U.S. adults eligible for inclisiran
high-risk primary prevention
5.4 million
diabetes
6.5 million
secondary prevention
8.0 million
Observational data: associations, not effects.
Further findings
Preventable ASCVD events with inclisiran · over 10 years
risk reduction
Distribution of preventable ASCVD events
- Most preventable ASCVD events occurred among males and White patients
Original publication
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States. JACC Adv. Published 20 January 2026. doi:10.1016/j.jacadv.2025.102517
Summarised from the published abstract; every number is checked against it